Biotechnology News

Browse the latest Biotechnology news. Use the menu or navigation tiles to change industry or topic.

January 23, 2026 08:00 ET | Source: Adagene Inc.

Adagene Provides Business Update and 2026 Objectives

Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December...
January 23, 2026 08:00 ET | Source: Ocugen

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously...
January 23, 2026 07:30 ET | Source: Sanara MedTech Inc.

Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance

FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on...
January 23, 2026 07:00 ET | Source: NextCure

NextCure Provides Business Update

SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE...
January 23, 2026 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic indgår distributionsaftale med Eurofarma for at udvide adgangen til chikungunya-vacciner i Brasilien

Aftalen muliggør den første markedslancering i Latinamerika for Bavarian Nordics chikungunya‑vaccineRummer mulighed for udvidelse til at dække resten af Latinamerika KØBENHAVN, Danmark, 23. januar...
January 23, 2026 02:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

Bavarian Nordic has signed a distribution agreement with Eurofarma for its chikungunya vaccine in Brazil with potential to expand to rest of Latin America
January 22, 2026 17:00 ET | Source: Vaxcyte, Inc.

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study...
January 22, 2026 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
January 22, 2026 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February...
January 22, 2026 13:42 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders...